Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis

Key facts

Sponsor

GeneCradle Inc

Intervention

GC304(genetic)

Enrollment

7 target

Eligibility

18-60 years · All sexes

Timeline

2024 – 2028

Study locations (1)

• Peking Union Medical College, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Holt-Oram syndrome

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNCT03895645
  Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGNANCT07352683
  Open TAP-block in Pediatric Abdominal Surgery
  Uppsala University
• RECRUITINGNANCT07301489
  Akershus Cardiac Examination (ACE) 5 Study
  University Hospital, Akershus
• RECRUITINGPHASE3NCT07000357
  A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
  AstraZeneca
• RECRUITINGPHASE1NCT06995729
  A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
  Pfizer
• RECRUITINGNCT06761105
  Using Anonymous Data From A Digital Tool for Medical History-Taking To Improve Healthcare Services
  University Hospital Goettingen
• ACTIVE NOT RECRUITINGPHASE2NCT06897748
  A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
  AstraZeneca
• ACTIVE NOT RECRUITINGNCT06735742
  A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
  Pfizer

See all trials for Holt-Oram syndrome →